Recently, the effectiveness of carbetocin has been evaluated in low- and middle-income countries because, unlike oxytocin, it can be used at ambient temperatures and thus may have the potential to be more effective in preventing PPH. This evidence concerns the gene OXT and pulmonary arterial hypertension.